
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Discontinuation of ACA Subsidies Will Leave Many Uninsured: Ciara Zachary, PhD, MPH
2
ncRNAs Linked to CLL Outcomes, Meta-Analysis Finds
3
BMI in CAR T: Overweight Status Predicts Worse MM Outcomes
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5












































